Cerebrospinal fluid levels of orexin‐A are not a clinically useful biomarker for Huntington disease
- 23 June 2006
- journal article
- Published by Wiley in Clinical Genetics
- Vol. 70 (1) , 78-79
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Biomarkers for neurodegenerative diseasesCurrent Opinion in Neurology, 2005
- CSF Hypocretin Levels are Normal in Huntington's Disease PatientsSLEEP, 2005
- Normal hypocretin-1 (orexin-A) levels in the cerebrospinal fluid of patients with Huntington's diseaseBrain Research, 2005
- Orexin loss in Huntington's diseaseHuman Molecular Genetics, 2004
- Relationship between CSF hypocretin levels and hypocretin neuronal lossExperimental Neurology, 2003